{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:22:02Z","timestamp":1791490922698,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"6B","license":[{"start":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T00:00:00Z","timestamp":1437177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2016,6]]},"abstract":"\n Objective<\/jats:title>\n \n To evaluate the outcome of patients after surgical resection of isolated retroperitoneal lymph node (\n RPLN<\/jats:styled-content>\n ) recurrence of renal cell carcinoma (\n RCC<\/jats:styled-content>\n ) using a multicentre international cohort.\n <\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n In all, 50 patients were identified who underwent resection of isolated\n RPLN<\/jats:styled-content>\n recurrence of\n RCC<\/jats:styled-content>\n at four institutions after nephrectomy for pT\n any<\/jats:sub>\n N\n any<\/jats:sub>\n M0 disease. Progression\u2010free (\n PFS<\/jats:styled-content>\n ) and cancer\u2010specific survival (\n CSS<\/jats:styled-content>\n ) were estimated using the Kaplan\u2013Meier method. Cox proportional hazards regression models were used to assess the association of clinicopathological characteristics with disease progression.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The median (interquartile range,\n IQR<\/jats:styled-content>\n ) age at resection was 57.0\u00a0(50.0\u201362.5)\u00a0years. The median (\n IQR<\/jats:styled-content>\n ) time to\n RPLN<\/jats:styled-content>\n recurrence after nephrectomy was 12.6\u00a0(6.9\u201339.5)\u00a0months, with no significant difference in median time to\n RPLN<\/jats:styled-content>\n recurrence between patients with N+ disease at nephrectomy (10.7\u00a0[6.5\u201324.6]\u00a0months) and those with Nx\/pN0 disease at nephrectomy (13.7\u00a0[8.7\u201344.2]\u00a0months) (\n P<\/jats:italic>\n = 0.66). The median (\n IQR<\/jats:styled-content>\n ) size of the\n RPLN<\/jats:styled-content>\n recurrence before resection was 2.6\u00a0(1.9\u20135)\u00a0cm. The most common site for\n RPLN<\/jats:styled-content>\n recurrence was within the interaortocaval region (34%). The median (\n IQR<\/jats:styled-content>\n ) follow\u2010up after\n RPLN<\/jats:styled-content>\n resection for patients alive at last follow\u2010up was 28.0\u00a0(13.7\u201351.2)\u00a0months. During follow\u2010up, 26 patients developed\n RCC<\/jats:styled-content>\n recurrence, at a median (\n IQR<\/jats:styled-content>\n ) of 9.9\u00a0(4.0\u201318.5)\u00a0months after\n RPLN<\/jats:styled-content>\n resection. Of those who developed a secondary recurrence, disease was again isolated to the retroperitoneum in seven patients. In all, 11 patients subsequently died, including 10 who died from disease. The median\n PFS<\/jats:styled-content>\n after\n RPLN<\/jats:styled-content>\n resection was 19.5\u00a0months, with a 3\u2010 and 5\u2010year\n PFS<\/jats:styled-content>\n of 40.5% and 35.4%, respectively. We also found that\n RPLN<\/jats:styled-content>\n recurrence at \u226412\u00a0months after nephrectomy was associated with a significantly inferior median\n PFS<\/jats:styled-content>\n (12.3\u00a0months) compared with\n RPLN<\/jats:styled-content>\n recurrence at >12\u00a0months after nephrectomy (47.6 months;\n P<\/jats:italic>\n = 0.003). Moreover, on multivariate analysis, a shorter time to recurrence remained associated with a significantly increased risk for subsequent disease progression (hazard ratio 3.51;\n P<\/jats:italic>\n = 0.005).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Surgical resection of isolated\n RPLN<\/jats:styled-content>\n recurrence from\n RCC<\/jats:styled-content>\n may result in durable cancer control in appropriately selected patients. Recurrence at \u226412\u00a0months after nephrectomy was associated with a significantly increased risk of progression after resection, underscoring the importance of this variable for risk stratification. Thus, we recommend that, in the setting of isolated\n RPLN<\/jats:styled-content>\n recurrence of\n RCC<\/jats:styled-content>\n (in patients without precluding comorbidities), careful consideration with the patients and medical oncology colleagues be undertaken about the relative and individualised benefits of surgical resection, systemic therapy, and surveillance.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.13212","type":"journal-article","created":{"date-parts":[[2015,6,27]],"date-time":"2015-06-27T01:00:20Z","timestamp":1435366820000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma"],"prefix":"10.1111","volume":"117","author":[{"given":"Christopher M.","family":"Russell","sequence":"first","affiliation":[{"name":"University of South Florida Morsani College of Medicine Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Lue","sequence":"additional","affiliation":[{"name":"University of South Florida Morsani College of Medicine Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fisher","sequence":"additional","affiliation":[{"name":"University of South Florida Morsani College of Medicine Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[{"name":"McGill University Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schwaab","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Tanguay","sequence":"additional","affiliation":[{"name":"McGill University Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Houston","family":"Thompson","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley C.","family":"Leibovich","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"Hanzly","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center Tampa FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000148261.19532.2c"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66077-6"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63541-9"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06616.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.05.111"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11851"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64675-5"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000132126.85812.7d"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25836"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.05.006"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000177487.64651.3a"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66529-7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.01.043"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.12.015"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00334-4"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66078-8"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11422"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.03.025"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.02.010"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67350-8"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000020050"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000129815.91927.85"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.08.042"},{"key":"e_1_2_6_29_1","unstructured":"National Cancer Institute.E2810 \u2013 Randomized Double\u2010Blind Phase III Study of Pazopanib vs Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy. In ClinicalTrials.gov [Internet].Bethesda MD:National Library of Medicine (US) 2000. NLM Identifier: NCT01575548. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01575548. Accessed April 2015"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13212","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.13212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.13212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:25:51Z","timestamp":1761740751000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.13212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,18]]},"references-count":28,"journal-issue":{"issue":"6B","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/bju.13212"],"URL":"https:\/\/doi.org\/10.1111\/bju.13212","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,18]]},"assertion":[{"value":"2015-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}